This Week in Oncology — Oct 7, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning new ways to overcome treatment resistance in breast and pancreatic cancer, the growing role of immunotherapy before surgery and transplant, advances in hematologic malignancies, and supportive care and prevention trials that test what actually helps patients. Let's dive in.

Our first theme is resistance, and how new agents are being layered onto established backbones in two cancers where options have been thin. In the New England Journal of Medicine, Mayer and colleagues report the phase 3 evERA trial, which enrolled 373 patients with estrogen receptor positive, HER2 negative advanced breast cancer whose disease had progressed after a CDK4 and 6 inhibitor plus endocrine therapy [1]. Patients were randomized to an all-oral combination of the oral selective estrogen receptor degrader giredestrant plus everolimus, or to standard endocrine therapy plus everolimus. Among patients with ESR1-mutated tumors, median progression-free survival nearly doubled, from about five and a half months to ten months, which corresponds to roughly a sixty percent reduction in the risk of progression or death. In the overall population the benefit was smaller but still statistically significant, with median progression-free survival of just under nine months versus five and a half, and the authors note the gain was driven mainly by the ESR1-mutated group. Toxicity was similar between arms, with stomatitis affecting close to half of patients in each group. This is a single open-label trial with progression-free survival as the primary end point, and overall survival is not yet reported, but it adds randomized evidence for an oral degrader-based combination in the post-CDK4 and 6 setting, particularly when an ESR1 mutation is present.

Pancreatic cancer has been called a drug graveyard, and a perspective in Clinical Cancer Research from Yu, Maitra and colleagues argues that this label may finally be outdated [2]. The authors point to the regulatory approval of the RAS inhibitor daraxonrasib for adults with previously treated metastatic pancreatic ductal adenocarcinoma, or those who are not candidates for multiagent therapy, and they survey the wave of RAS-targeted agents now in phase 3 trials. It is a review rather than new data, and the authors are explicit that the current generation of trials will determine whether these strategies deliver durable survival gains. Taking a very different approach, Garcia-Carbonero and colleagues report in Nature Medicine a randomized phase 2b trial of VCN-01, an intravenous oncolytic adenovirus engineered to express hyaluronidase, added to gemcitabine and nab-paclitaxel as first-line therapy for metastatic pancreatic cancer [3]. In the intention-to-treat population of about one hundred patients, median overall survival was roughly ten and a half months versus eight and a half, a difference that was not statistically significant. The authors report that the overall survival endpoint was met in their prespecified full analysis set, and progression-free survival and duration of response favoured the virus arm, with about a third of patients alive at eighteen months versus under a tenth with chemotherapy alone. Response rates and CA 19-9 levels did not differ, and serious virus-related events occurred in just under a quarter of patients. Given the small size, open-label design and mixed primary results, the authors themselves frame this as justification for a blinded phase 3 trial rather than a practice change.

Our second theme is immunotherapy given before definitive local treatment, where long-term data are now maturing. In Nature Medicine, Long and colleagues from the International Neoadjuvant Melanoma Consortium pooled 1,038 patients with resectable stage three melanoma treated across 26 sites with neoadjuvant checkpoint inhibitors, BRAF and MEK inhibitors, or combinations [4]. Five-year recurrence-free survival was about three quarters with anti-PD-1 combined with another immunotherapy agent, about sixty percent with anti-PD-1 alone, and under forty percent with BRAF and MEK inhibitors. The most striking finding concerns patients who achieved a major pathological response to checkpoint inhibitors: their five-year overall survival was close to ninety-nine percent, and they gained no apparent benefit from continuing immunotherapy after surgery. Pooled data from trial and non-trial settings carry selection biases, and the comparisons across regimens are not randomized, but this strengthens the case that pathological response can guide postoperative decisions and that targeted therapy alone performs poorly in the neoadjuvant setting. Moving to the liver, Ong and colleagues report in JAMA Oncology a retrospective, propensity-matched study of 416 transplant recipients in China whose hepatocellular carcinoma was initially beyond the Milan criteria [5]. Patients who received a checkpoint inhibitor-based downstaging strategy before transplant had a median overall survival of about four and a half years versus two and a half years without, and roughly a forty percent lower risk of recurrence or death. The trade-off was that acute rejection within ninety days roughly doubled, to about one in six recipients. As an observational study from high-volume centres, it cannot establish causation, but it adds to evidence that pretransplant immunotherapy may be feasible and associated with benefit, with rejection risk as the key unresolved safety question.

Our third theme covers hematologic malignancies, where regulatory and guideline activity has been brisk. In Clinical Cancer Research, Ershler and colleagues summarize the FDA's traditional approval of the bispecific antibody epcoritamab combined with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, based on the randomized EPCORE FL-1 trial of 488 patients [6]. Adding epcoritamab cut the risk of progression or death by roughly four fifths compared with lenalidomide and rituximab alone, and overall response rose to ninety-six percent. The summary also highlights a regulatory model in which a single randomized trial supports both accelerated and traditional approval. In transplantation, the Journal of Clinical Oncology publishes a phase 3 trial from Qiao and colleagues in which 190 patients undergoing haploidentical or unrelated donor transplant received antithymocyte globulin-based prophylaxis with or without high-dose sitagliptin [7]. Grade two to four acute graft-versus-host disease by day one hundred fell by more than half, from about a third of patients to about fifteen percent. Reductions in severe and intestinal disease were exploratory, and there was no difference in chronic graft-versus-host disease, relapse, or overall survival at two years. This is an open-label trial from a single country, so confirmation in other prophylaxis backbones, including post-transplant cyclophosphamide, is still needed. Also in the Journal of Clinical Oncology, Banerjee and colleagues publish the latest update of the ASCO living guideline on multiple myeloma treatment [8]; the abstract describes the living guideline process rather than specific recommendations, so the details are best read in the full document.

Our final theme is prevention and supportive care, where two pragmatic trials test interventions that are cheap but not always effective. In JAMA, Hart and colleagues randomized 3,259 medically underserved adults who smoked and were referred for lung cancer screening at four health systems in the United States [9]. Sustained, biochemically confirmed abstinence at six months was low across the board, but adding financial incentives of up to six hundred dollars roughly doubled quit rates compared with usual ask-advise-refer care, to just under nine percent. Free pharmacotherapy on its own was not superior to usual care, and adding a mobile health tool did not improve on incentives. The trial supports incentive-based programmes within screening for this population, though absolute quit rates remain modest. In Annals of Oncology, Lendorf and colleagues report the CryoPac trial of frozen gloves and socks during taxane chemotherapy in 268 patients [10]. The primary endpoint was negative: neuropathy at the end of treatment was common in both arms, about three quarters of patients with cryotherapy versus just over four fifths with usual care, a difference that was not statistically significant. Patient-reported tingling and numbness and sensory testing did favour cryotherapy, but compliance was only about two thirds and many patients dropped out, so the evidence remains inconclusive pending longer follow-up for persistent neuropathy.

If you only have time for one paper this week, make it the evERA trial in the New England Journal of Medicine [1]. It provides phase 3 evidence for an all-oral degrader combination after CDK4 and 6 inhibitor progression, reopening the question of how best to sequence therapy in ESR1-mutated breast cancer.

Here is what this week's evidence adds up to in Oncology. First, an oral estrogen receptor degrader plus everolimus improved progression-free survival after CDK4 and 6 inhibitors, most clearly with ESR1 mutations, though survival data are pending. Second, neoadjuvant immunotherapy in melanoma now has five-year data showing excellent survival after major pathological response, supporting response-adapted care, while pretransplant immunotherapy for liver cancer looks promising but rests on observational data with higher rejection. Third, pancreatic cancer is seeing genuine momentum with RAS inhibition, whereas the oncolytic virus results are mixed and need phase 3 confirmation. Fourth, in hematology, epcoritamab with lenalidomide and rituximab substantially improved disease control in relapsed follicular lymphoma, and sitagliptin reduced acute graft-versus-host disease without a survival effect. Finally, financial incentives outperformed free medication for smoking cessation in underserved screening patients, and cryotherapy did not meet its primary goal for preventing taxane neuropathy.

That's your roundup for This Week in Oncology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.